

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement

A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*

A description of all covariates tested

A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Olympus FV31S-SW software, PerkinElmer Living Image software, ParaVision software, NRecon software, SPSS software, Microsoft Excel.

Data analysis Softwares used for analysis include GraphPad Prism 8.0, Image J, Living Image, RadiAnt DICOM Viewer software, CTAn software, SPSS software, Microsoft Excel.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study are available within this published article and its Supplementary Information files will be available from the corresponding author upon reasonable request.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	not applicable
Population characteristics	not applicable
Recruitment	not applicable
Ethics oversight	not applicable

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Details of the sample sizes for all experiments are shown in the captions of the figures, and reasonable sample sizes were chosen to ensure reasonable between-group statistics were performed.
Data exclusions	No data were excluded.
Replication	The experiments were repeated according to the set steps to verify that the results were reproducible.
Randomization	The mice used in the experiment were randomly assigned to the treatment group.
Blinding	During the data collection and analysis process, the researchers were unaware of the assigned groupings.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Eukaryotic cell lines

Policy information about [cell lines](#) and [Sex and Gender in Research](#)

Cell line source(s) MDA-MB-231, A549, PANC-1, B16F10 and HUVECs.

Authentication Cell lines were authenticated by Short Tandem Repeat (STR) test.

Mycoplasma contamination No mycoplasma contamination was found in the assay experiments for all cells.

Commonly misidentified lines  
(See [ICLAC](#) register) None of the cell lines used in this study were present in ICLAC.

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals BALB/c nude mice and C57 mice (4-6 weeks, female, with an average of 18 g) were purchased from Shanghai JieSiJie Laboratory Animals Co. LTD.

Wild animals This study did not involve wild animals.

Reporting on sex The model system was a spinal metastasis model of breast cancer, and males do not have the possibility of developing breast cancer, so only female rats were selected. To ensure the consistency of the animal model, female rats were subsequently used in lung cancer, pancreatic cancer, and melanoma.

Field-collected samples This study did not involve biological samples collected from the field.

Ethics oversight All animal experiment protocols were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals approved by the Animal Experimentation Ethics Committee of Zhongshan Hospital, Fudan University.

Note that full information on the approval of the study protocol must also be provided in the manuscript.